Blue test tubes arranged in a line, disappearing into the background

Drug news

Torisel (Pfizer) fails in combination trial with Avastin in Renal Cell Carcinoma

Read time: 1 mins

Last updated:11th Aug 2012

Published:11th Aug 2012

Source: Pharmawand

Pfizer Inc. announced that the Phase III INTORACT trial (B1771006), evaluating the combination of bevacizumab plus Torisel (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-?-2a) in the first-line treatment of patients with advanced Renal Cell Carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population. Additional efficacy endpoints and safety data for the combination treatments in both arms are being analyzed and will be presented at an upcoming major medical congress.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

One-year histologic outcomes reported in phase III study of mirikizumab compared to ustekinumab for Crohn's disease

Eli Lilly and Company announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience

3 mins

Drug news

FDA approves Hympavzi (marstacimab-hncq) for the treatment of adults and adolescents with hemophilia A or B without inhibitors

Pfizer Inc. announced that the FDA has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors

1 min

Drug news

Updated 2024-2025 Nuvaxovid COVID-19 Vaccine ((NVX-CoV2705),) receives authorization in the EU

9 October 2024 -Novavax, Inc. announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union (EU)

1 min

See all news